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Abstract
 LMO2 and its binding partner  TAL1/SCL have essential roles in both hematopoiesis and 
angiogenesis. Indeed,  LMO2 is highly expressed in endothelial cells and hematopoietic 
stem cells (HSCs) almost exclusively (with exceptions) throughout life. Recently, the first 
birthplace of HSCs has been identified as hemogenic endothelial cells in the dorsal aorta in 
mammals. Firstly, the  LMO2 complex including  TALI,  GATA1/2/3 (i. e., GATA1 or 
GATA2 or GATA3), and  LDBI play a key role in endothelial to hemogenic endothelial cell 
transition in the dorsal aorta in producing HSCs. Another role of the  LMO2 complex is to 
remodel the existing vascular system in angiogenesis. In 2007 and 2012, progress was 
made in dissecting the mechanism of vascular remodeling regulated by the  LMO2 complex. 
Two of the pivotal role players in vascular remodeling, VE-cadherin and angiopoitin-2, 
were identified to be among the direct targets of the  LMO2 transcription factor complex. 
In this review, the detailed mechanism in vascular remodeling via the  LMO2 complex is 
discussed.
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Introduction: endothelial phenotype conversion
 Remarkable progress has been made in recent 
years to identify the origin of the first blood cell. 
Studies have shown that the first hematopoietic 
stem cells (HSCs) are generated from a hemogenic 
endothelium intermediate, which is derived from 
endothelial cells of the dorsal aorta floor in ver-
tebrates. This two-step transition of endothelial 
cells finally produces HSCs. The first step, tran-
sition from endothelium to hemogenic endo-
thelium intermediate, requires a basic-helix-loop-
helix (bHLH) transcription factor  TALI, the 
LMO2 binding partner. On the other hand, the 
second step, transition from hemogenic endo-
thelium intermediate to HSC, needs the RUNX1 
transcription factor (Chen et al., 2009). 
 Both LMO2 and  TALI_ were identified at the 
breakpoints of reciprocal chromosomal trans-
locations associated with T cell acute lympho-
blastic leukemia (Rabbitts, 1994). Gene knockout 
studies of both LMO2 and  TALI showed a similar 
bloodless phenotype which is embryonic lethal at 
around E9.5-  E10.5 (Terano et al., 2005). In addi-
tion, LMO2 and  TALI bind to each other to form a
transcription factor complex including also E47, 
LDB1 and GATA1/2/3 (hereafter referred to as 
the LMO2 complex) (Fig. 1) (Wadman et al., 1997). 
At present, one of the probable functions (maybe 
not the first) of the LMO2 complex is to convert 
 "ordinary" endothelium into hemogenic endo-
thelium intermediate (endothelium, which has a 
potential to differentiate into HSC). Neither 
LMO2 nor  TALI is required in the process of 
vasculogenesis, de novo differentiation of endo-
thelium from mesoderm (as discussed in more 
detail later), because an immature capillary 
network exists in both Lmo2-/- and Tall-/- mice. 
Once HSCs are produced,  TAD is dispensable for 
HSC's multipotency,  self-renewal, and long-term 
repopulating activity (Mikkola et al., 2003).
The role of LMO2 and  TALI in angiogenesis
 Our vascular system is constructed by two 
distinct systems, vasculogenesis and angiogenesis. 
Vasculogenesis is a process in which a primary 
capillary network is formed from unspecified 
mesoderm. Then, a more mature vascular sys-
tem is made through a process called angiogene-
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Schematic presentation of the LMO2 transcription factor complex. This 
complex recognizes the  Ebox-GATA sequences on DNA and regulates 
downstream genes
sis. Angiogenesis involves the remodeling of an 
existing capillary network to a more complex 
vascular network. Several years after a bloodless 
phenotype of Lmo2-/- and Tall-/- mice was 
reported, the essential roles of LMO2 and  TALI 
in angiogenesis were clarified (Visvader et al., 
1998; Yamada et al., 2000). From the present 
standpoint, the initiation of definitive hemato-
poiesis is depends totally on angiogenesis because 
HSCs are produced from endothelium of the 
dorsal aorta floor. In other words, angiogenesis 
is prerequisite for definitive hematopoiesis. 
Therefore, the bloodless phenotype seen in both 
Lmo2-/- and Tall-/- mice is now (not at the time of 
discovery) a foreseeable result of severe defects in 
angiogenesis due to gene knockout. LMO2 is 
almost exclusively expressed in endothelium 
throughout life (Yamada et al., 2000), and  TALI is 
also expressed in endothelium. The whole story 
led us to speculate on the role of the LMO2 
complex in angiogenesis. In 2007, Deleuze et al. 
reported very important results about this 
(Deleuze et al., 2007).
The LMO2 complex up-regulates VE-cadherin
 VE-cadherin (vascular endothelial cadherin) 
mediates adhesion between endothelial cells and 
plays an important role in vascular morpho-
genesis. It is a classical cadherin from the 
cadherin superfamily and a calcium-dependent 
cell-cell adhesion glycoprotein composed of five 
extracellular cadherin repeats, a transmembrane 
region, and a highly conserved cytoplasmic tail. 
Although it is dispensable for vasculogenesis, it is
essential for angiogenesis.  VE-cadherin knockout 
in mice resulted in embryonic lethality at E9.5 due 
to lack of proper vascular development (Carmeliet 
et al., 1999). Nascent vessels collapsed or disas-
sembled in the absence of VE-cadherin. VE-
cadherin is also known to be required for  main-
taining a restrictive endothelial barrier and con-
trol endothelial permeability. Deleuze et al. re-
ported that the LMO2 complex up-regulates VE-
cadherin expression in endothelial cells. First, 
they performed a  TALI knockdown experiment 
using small interfering RNA (siRNA) in vitro and 
found that  TAL1 knockdown disrupts endothelial 
morphogenesis in 2D Matrigel or 3D Collagen I 
gel HUVEC culture without affecting cell survival. 
The abnormal intercellular contacts observed in 
both 2D and 3D networks formed with endothelial 
cells (ECs) lacking  TALL This result suggested 
that the important cell-cell adhesion molecules 
were down-regulated in  TALI lacking ECs. As 
mentioned above, VE-cadherin is one of the strong 
candidates for such molecules and, in fact, VE-
cadherin expression was significantly down-
regulated in  TALI lacking ECs. Secondly, they 
found that knockdown of E47 and  LM02, both 
 TALI binding partners, also down-regulated VE-
cadherin expression. Because E47,  TALI,  LM02, 
LDB1, and GATA2 form a transcription factor 
complex, this strongly indicated a transcription 
factor complex composed of E47,  TALI,  LM02, 
LDB1, and GATA2 (the LMO2 complex) up-
regulated VE-cadherin during angiogenesis. 
Chromatin immunoprecipitation (ChIP) assay 
using the VE-cadherin promoter sequence com-
firmed that  TALI, E47,  LM02, and GATA2 were
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actually recruited to the VE-cadherin promoter, 
and VE-cadherin promoter activity depended on 
a specialized Ebox-GATA element which is an 
essential sequence for the LMO2 complex binding. 
This result as a whole shows that the LMO2 
complex is a direct upstream transcription factor 
complex of VE-cadherin.
VEGF signal and VE-cadherin
 Homophilic interactions between VE-cadherin 
molecules at adherens junctions in adjacent 
endothelial cells help maintain the endothelial 
barrier. Upon vasculo-endothelial growth factor 
(VEGF) exposure, activation of VEGF Receptor2 
(R2), also known as FLK-1, triggers a phosphory-
lation cascade that targets VE-cadherin which 
results in phosphorylation of Y685 by src and S665 
by PAK. VEGF R2 contributes to signal after 
internalization, while sequestration of VE-
cadherin in endosomes disrupts adhesion. This 
process promotes loss of cell-cell contacts, in-
creases vascular permeability, and endothelial cell 
migration. In this mechanism via VE-cadherin, the 
VEGF signal promotes vascular remodeling 
(angiogenesis).
Angiogenesis through angiopoietin/Tie-2 axis
 The Tie receptors and their angiopoietin (Ang) 
ligands have been identified as the second vas-
cular tissue-specific receptor Tyr kinase system. 
Ang-Tie signaling is essential during embryonic 
vessel assembly and maturation, and it functions 
as a key regulator of adult vascular homeostasis. 
Ang-1- and Tie-2- deficient mice have largely 
complementary mid-gestational lethal pheno-
types, resulting from defects in vascular re-
modeling and vessel maturation (Sato et al., 1995; 
 Suri et al., 1996). Ang-2-deficient mice have only 
mild blood vascular defects (Gale et al., 2002). In 
contrast, global overexpression of Ang-2 causes a 
phenotype that is reminiscent of Ang-1 or Tie-2 
deficiency. These genetic studies have estab-
lished Ang-1 as the nonredundunt agonistic Tie-2 
ligand, whereas Ang-2 is considered to be the 
antagonist of Ang-1/Tie-2 signaling. This concept 
has more recently been supported by genetic and 
biochemical studies establishing a role for 
endothelium-derived Ang-2 as a negative regu-
lator of Tie-2 phosphorylation. Ang-2 primes and 
activates endothelium to respond to other angio-
genic factors and destabilizes vessel coverage by 
pericytes, an essential step in initiating angio-
genesis.
Angiopoietin-2: Another direct transcriptional 
target of LMO2 complex
 LYL1 belongs to the class II basic helix-loop-
helix transcription family and its basic helix-loop-
helix sequence shows remarkable similarity with 
that of  TALL LYL1 also forms a complex with 
LMO2 and could thus, be another member of the 
LMO2 transcription factor complex. Deleuze et 
al. also showed that LMO2 played a central role in 
assembling TAL1-E47,  LYLl-LYL1 or/and  LYL1-
TALI dimers with GATA2. The resulting LMO2 
complex recognizes a highly conserved Ebox-
GATA composite element, which lies in the Ang-
2 promoter and up-regulates its expression 
(Deleuze et al., 2012).
The LMO2 complex binding site is highly con-
served in the promoter region of angiogenesis-
related transcription factors
 Since the LMO2 complex has been identified as 
a master transcription factor complex for hemato-
poiesis, which plays a critical role in the emer-
gence of hematopoietic stem cells, the search for 
the LMO2 complex binding site composed of 
Ebox-GATA composite elements among the pro-
moter sequences of hematopoiesis-related genes 
has been carried out. 
 Now that the LMO2 complex role in angiogene-
sis has been revealed and members of the LMO2 
transcription factor complex have been found in 
promoter regions of important angiogenesis play-
ers such as VE-cadherin and Ang-2, a similar 
search in promoter regions of angiogenesis-
related genes has begun. Interestingly, the 
analysis of the promoter sequences coming from 
known angiogenesis-related factors using the 
MATINSPECTOR program in the TRANSFAC 
database showed that the binding site of the 
LMO2 complex is highly conserved in the 
promoter regions of these factors (Lee et al., 2003).
Transcriptional modulation of endothelial cell 
development
 The transcription factors that regulate endo-
thelial cell development have been a focus of 
active research for several years, and many 
players in the endothelial transcriptional program 
have been identified (Tablel). They include 
members of the Sox, Ets, Forkhead, GATA , and 
Kruppel-like families. Some, such as the Ets 
transcription factor Etv2, are involved in the 
process of vasculogenesis and hematopoiesis, and
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Table 1 Knockout mice phenotype of the LMO2 complex related genes
Gene Lethality Phenotype Reference
LMO2  complex
Lmo2  E9.5—E10.5
Defect in both primitive and definitive hematopoesis.
Defect in angiogenesis.
(Yamada et al., 1998)
(Yamada et al., 2000)
Tall E9.5
Defect in both primitive and definitive hematopoiesis.
Defect in yolk sac angiogenesis.
(Robb et al., 1995)
(Visvader et al., 1998)
E2A Neonatal
B lymphocyte differentiation block.
Acute T cell lymphoma. (Yan et al., 1997)
Ldbl E9.5 Severe defect in mesoderm specification, including blood island of yolk sac. (Mukhopadhyay et al., 2003)
Gata2 E10.5 Defect in definitive hematopoiesis. (Tsai et al., 1994)
Downstream
VE-cadherin E9.5 Defect in angiogenesis. (Carmeliet et al., 1999)
Ang2 No Defect in postnatal angiogenesis. (Gale et al., 2002)
 Upstream
Etv2 E9.5 Lack of vasculogenesis. (Lee et al., 2008)
Flil  E12.5
Defect in hematopoiesis.
Disruption of vessel integrity.
(Spyropoulos et al., 2000)
others are solely involved in angiogenesis. The 
uniqueness of the LMO2 transcription factor 
complex is its dispensability in vasculogenesis and 
its key role in hematopoietic stem cell (HSC) 
production. LMO2 is also indispensable for blood 
vessel sprouting (sprouting angiogenesis) 
(Yamada et al., 2002).
Upstream of the LMO2 complex
Ets  transcription  factors regulate mesoderm speci-
fication  of  endothelial and hematopoietic lineages 
 The E-twenty-six (ETS) family is a large group 
of proteins (named after its homology with v-ets 
oncogene in the E26 retrovirus), with close to 
thirty members in human and mouse, that 
achieves transcriptional regulation by binding 
clusters of ETS binding motifs on gene enhancers 
and promoters. This conserved core DNA se-
quence is 5'-GGA(A/T)-3', and a lot of endothelial 
genes have multiple ETS binding sites in their 
enhancer or promoter. Hemangioblasts, common 
precursors of endothelial and hematopoietic ells, 
are specified from ventral mesoderm during the 
process of vasculogenesis.  Flil and Etv2 are 
members of Ets transcription factors and have 
recently been identified as master transcription 
factors for vasculogenesis. LMO2 complex mem-
bers such as  LM02,  TALI, and GATA2, are up-
regulated by these two Ets transcription factors.
Etv2: a transcription factor which triggers vascu-
logenesis and LMO2 expression 
 During embryogenesis, the endothelial and the 
primitive erythropoietic lineages first appear 
during gastrulation in the blood islands of the yolk
sac. Etv2 expression is present at the very early 
stages of vascular development in the mouse, with 
expression detected in the blood islands of the 
yolk sac, and in the earliest vessels in the embryo. 
Notably, Etv2 expression begins decreasing 
within endothelial cell populations by E9.5 and is 
essentially extinguished in those lineages by  E10. 
5, suggesting an involvement of this transcription 
factor in early vascular development. Etv2 null 
mice have severe defects in vasculogenesis and 
primitive hematopoiesis.  Etv2-/- embryos die at 
midgestation and lack any detectable embryonic 
vessels, blood islands in the yolk sac, or endothelial 
progenitors (Ferdous et al., 2009; Lee et al., 2008). 
Expression of early vascular markers such as 
Flkl, PECAM, and Tie2, is almost completely 
abolished in the absence of Etv2. Hemangioblasts 
are apparently not differentiated from ventral 
mesoderm without Etv2. Interestingly, Etv2 
binds to the LMO2 enhancer and transactivates 
its expression (Koyano-Nakagawa et al., 2012). 
LMO2 plays a critical role in primitive red blood 





 In primitive hematopoiesis (yolk sac erythro-
poiesis), the blood islands produce the first vas-
cular progenitors in the yolk sac of mammals. 
Simultaneously, the primitive red blood cells are 
born in the inner surface of the islands. The 
LMO2 complex, as well as  Flil, are necessary for 
this primitive red cell specification. We still don't 
know when this hematopoietic lineage specifica-
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tion occurs. Most likely, blood islands are  com-
posed of bi-potent  hemangioblasts, which have the 
potential to differentiate into both  hematopoietic 
and endothelial cells. After the production of the 
 primitive red blood cells, the vascular progenitors 
 form a vascular plexus, which is then  remodeled 
into  more  mature blood vessels through the 
process of angiogenesis.  TALI is essential for 
this angiogenic process (Visvader et al., 1998). 
 In definitive  hematopoiesis, which is  intra-
embryonic and produces the pluripotent  hemato-
poietic  stem cells (HSCs), the endothelial floor of 
the dorsal aorta is the birthplace of HSCs. 
Because the dorsal aorta is constructed by the 
process of angiogenesis, it is prerequisite for 
definitive  hematopoiesis. As  mentioned before, 
the LMO2  complex is essential for this angio-
gensis and for the transitional process of the 
aortic  endothelium into  hemogenic  endothelium. 
Without the LMO2  complex, no HSCs are pro-
duced  from the dorsal aorta. On the other hand, 
the HSCs produced are likely to play  some roles in 
following angiogenesis through Angl/Tie2 axis. 
Further research is needed to clarify the inter-
dependence of  hematopoiesis and angiogenesis.
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